Social anxiety is a common, but under-researched topic in the LGBTQIA+ community. We conducted a scoping review of studies between January 2014 and April 2024 that included LGBTQIA+ samples with social anxiety scales evaluating scales for outdated language. The search produced 1155 results out of which 17 articles fit the inclusion criteria. The results suggest that 47 % of the measures include items that reinforce heteronormative or cisnormative stereotypes and 29.4 % of studies included scales inappropriate for the population under investigation. Therefore, the wordings of certain items need to be adapted to fit the investigated population and a re-examination of the psychometric properties of the revised scales is needed.
17 December 2025 in Expert Review of Neurotherapeutics
Social anxiety disorder (SAD) is a common and disabling mental disorder that follows a chronic course unless it is treated with effective treatments. This systematic review examines randomized controlled trials (RCTs) of pharmacological treatments for adults with SAD published since 2015. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Search was conducted on PubMed, Scopus, Web of Science, and PsycINFO. Risk of bias of the included studies was assessed using the Cochrane risk of bias tool for randomized trials. Eighteen RCTs were included. Selective serotonin reuptake inhibitors (SSRIs) were the most investigated pharmacological intervention, either as monotherapy or in combination with cognitive behavioral therapy (CBT). More recent drugs show promising results include cannabidiol and d-cycloserine. When CBT is unavailable, SSRIs are the first-line pharmacological treatment for SAD based on current evidence. However, response rates vary substantially. We recommend a personalized approach that includes patient preference and treatment accessibility.
12 February 2025 in Expert Review of Neurotherapeutics
Many children are affected by social anxiety disorder (SAD). Pharmacotherapy, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), may be indicated, but a clear understanding of the risks and benefits associated with these pharmacological treatments is needed. This expert review explores the risks and benefits of pharmacotherapy for treating SAD in children. Pharmacotherapy may be considered as a treatment when symptoms are complex or severe or when effective psychotherapy, such as cognitive behavioral therapy (CBT), is not accessible. We recommend that clinicians collaborate closely with parents, pediatricians, and psychiatrists in the treatment planning process, while monitoring the effects of pharmacotherapy. Future research should prioritize the personalization of treatments.